Kinarus Therapeutics Holding AG

Equities

CURE

CH0009115129

Market Closed - Swiss Exchange Other stock markets 11:12:24 2024-05-03 am EDT			5-day change	1st Jan Change
9.754 ^CHF	-15.18%		-34.97%	+444.31%

Apr. 26	Kinarus Therapeutics Completes Merger with Unit, Rebrands as Curatis	MT
Apr. 25	Curatis AG completed the acquisition of Kinarus Therapeutics Holding AG for CHF 18.3 million in a reverse merger transaction.	CI

Kinarus Therapeutics Holding AG Signs Licensing Agreement to Extend Cash for Operations

August 25, 2023 at 12:01 pm EDT

Kinarus Therapeutics Holding AG signed licensing agreement to extend cash for operations. The financial consideration is immediately available to Kinarus and was required to ensure liquidity while Kinarus awaits transfer of funds from a convertible loan investment made by ChaoDian (Hangzhou) Investment Management Co (CDIM) made in May 2023. In exchange, the group of shareholders received an exclusive license to develop KIN001 to treat IPF; Kinarus is eligible to receive milestones and royalties, as is customary in biopharmaceutical licensing agreements.

Latest news about Kinarus Therapeutics Holding AG

Kinarus Therapeutics Completes Merger with Unit, Rebrands as Curatis	Apr. 26	MT
Curatis AG completed the acquisition of Kinarus Therapeutics Holding AG for CHF 18.3 million in a reverse merger transaction.	Apr. 24	CI
Swiss Exchange Regulator Drops Inquiry Into Kinarus Therapeutics	Mar. 28	MT
Kinarus Therapeutics Receives Swiss Court Approval for Revocation of Bankruptcy	Feb. 06	MT
Kinarus Therapeutics Shares Surge on Combination Deal With Curatis	Jan. 29	MT
Curatis AG entered into a transaction agreement to acquire Kinarus Therapeutics Holding AG in a reverse merger transaction.	Jan. 28	CI
Kinarus Therapeutics to File for Bankruptcy After Funding Efforts Fail	23-09-25	MT
Kinarus Therapeutics' H1 Loss Widens	23-08-31	MT
Kinarus Therapeutics Sells License for Lung Disease Treatment to Shareholder Group	23-08-28	MT
Kinarus Therapeutics Holding AG Signs Licensing Agreement to Extend Cash for Operations	23-08-25	CI
Kinarus Therapeutics’ Interim CFO Steps Down	23-07-12	MT
Kinarus Therapeutics Announces Personnel Changes	23-07-12	CI
Kinarus Therapeutics Secures Liquidity via Subordinated Bridge Loan Deals	23-06-27	MT
Kinarus Therapeutics Posts Higher FY22 Attributable Loss	23-05-31	MT
SIX Exchange Probes Kinarus Therapeutics Over Potential Disclosure Violation	23-05-19	MT
Kinarus Therapeutics Inks Convertible Loan Deal with Chinese Investor; Shares Drop 7%	23-05-11	MT
Kinarus Therapeutics Holding AG announced that it expects to receive CHF 1.5 million in funding from ChaoDian Investment Management Co., Ltd.	23-05-09	CI
Kinarus Therapeutics Secures Extension for FY22 Results Publication	23-04-28	MT
Kinarus Therapeutics Provides Update on Phase 2 Kinfast Covid-19 Clinical Trial Progress	23-02-21	CI
Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan	23-01-17	CI
Kinarus' COVID-19 Drug Shows Antiviral Efficacy Against Omicron Subvariants in Preclinical Study	22-12-06	MT
Kinarus Therapeutics Secures US Patent for Eye Drug KIN001	22-11-22	MT
Kinarus Therapeutics, Great Health Explore Partnerships for Mid-stage Trial of Eye, Lung Disease Drug in China	22-11-16	MT
Kinarus Therapeutics Mulls Funding Options for Mid-stage Studies of Eye, Lung Disease Drug	22-11-04	MT
Kinarus Therapeutics Swings to H1 Loss Amid Expenses Related to Investigational COVID-19 Drug Trial	22-08-31	MT

Chart Kinarus Therapeutics Holding AG

Duration

Period

More charts

Company Profile

Kinarus Therapeutics Holding AG is a Switzerland-based Company that operates as a biopharmaceutical industry engaged in diseases treatment. The Company conducts its work within clinical-stage area and its activities include discovery, examination and development of medicines that are intended for the treatment of viral, respiratory, and ophthalmic diseases. Kinraus therapeutic drug is patent protected KIN001 which is a combination of pamapimod and pioglitazone. KIN0001 offers oral, long-term treatment of diseases with severe impact on the comfort of living.

Sector

More about the company